ENVVENO MEDICAL CORP (NVNO) Stock Price, Forecast & Analysis
USA - NASDAQ:NVNO - US29415J1060 - Common Stock
NVNO Key Statistics, Chart & Performance
The current stock price of NVNO is 0.6567 USD. In the past month the price decreased by -10.93%. In the past year, price decreased by -79.88%.
NVNO Latest News, Press Relases and Analysis
NVNO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 219.11B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.92 | 206.56B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.21 | 149.52B | ||
| SYK | STRYKER CORP | 26.96 | 135.73B | ||
| IDXX | IDEXX LABORATORIES INC | 56.27 | 56.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.6 | 52.06B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.72 | 49.36B | ||
| RMD | RESMED INC | 25.26 | 36.50B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.01 | 33.55B | ||
| PODD | INSULET CORP | 70.1 | 22.55B | ||
| DXCM | DEXCOM INC | 29.48 | 21.51B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.97 | 17.58B |
Related stock screener links
About NVNO
Company Profile
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 37 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Company Info
ENVVENO MEDICAL CORP
70 Doppler
Irvine CALIFORNIA US
CEO: Robert Berman
Employees: 37
Phone: 19492612900
ENVVENO MEDICAL CORP / NVNO FAQ
Can you describe the business of ENVVENO MEDICAL CORP?
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 37 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
What is the stock price of ENVVENO MEDICAL CORP today?
The current stock price of NVNO is 0.6567 USD. The price increased by 1.3% in the last trading session.
Does ENVVENO MEDICAL CORP pay dividends?
NVNO does not pay a dividend.
How is the ChartMill rating for ENVVENO MEDICAL CORP?
NVNO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for ENVVENO MEDICAL CORP?
ENVVENO MEDICAL CORP (NVNO) has a market capitalization of 12.64M USD. This makes NVNO a Nano Cap stock.
NVNO Technical Analysis
NVNO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVNO. While NVNO has a great health rating, there are worries on its profitability.
NVNO Financial Highlights
Over the last trailing twelve months NVNO reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS increased by 18.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.89% | ||
| ROE | -74.59% | ||
| Debt/Equity | 0 |
NVNO Forecast & Estimates
6 analysts have analysed NVNO and the average price target is 12.75 USD. This implies a price increase of 1841.53% is expected in the next year compared to the current price of 0.6567.